Johnson & Johnson (JNJ)
J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use
The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ ) Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman and Chief Executive Officer Joseph Wolk - Executive Vice President, Chief Financial Officer Jennifer Taubert - Executive Vice President, Worldwide Chairman, Innovative Medicine John Reed - Executive Vice President, Innovative Medicine, R&D Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech Conference Call Participants Terence Flynn - Morgan Stanley Joshua Jennings - TD Cowen Alexandria Hammond - Wolfe Research Tim Anderson - Bank of America Lawrence Biegelsen - Wells Fargo Chris Schott - JPMorgan David Roman - Goldman Sachs Operator Good morning and welcome to Johnson & Johnson's Fourth Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.
J&J's Q4 Earnings Beat, Stock Down on Tepid 2025 Sales Guidance
JNJ beats estimates for fourth-quarter earnings and sales. Its sales guidance for 2025 falls short of expectations.
Johnson & Johnson slides as soft sales guidance casts shadow
Johnson & Johnson shares faced pressure on Wednesday as soft sales guidance for the coming year cast a shadow over expectation-beating fourth-quarter profit. Adjusted net earnings of US$4.95 billion were down 11.1% year on year in the fourth quarter, J&J reported, but ahead of consensus expectations for US$4.88 billion.
Compared to Estimates, Johnson & Johnson (JNJ) Q4 Earnings: A Look at Key Metrics
The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Trump Tariffs Take Shape, Stargate AI Project Ramps Up, JNJ & PG Beat
Kevin Green joins Morning Movers to look at how President Trump's tariffs plan could impact several areas of the market, specifically currencies and copper. Then, the focus shifts to Trump's ambitious A.I.
J&J Tops Q4 Adjusted Earnings Estimates, But 2025 Sales Outlook Falls Short
Johnson & Johnson (JNJ) posted its fourth-quarter earnings report Wednesday morning, with adjusted profits beating expectations while the company's sales projections for the coming fiscal year fell short.
Johnson & Johnson Tops Q4 EPS Forecasts
Pharmaceuticals and medical devices manufacturer Johnson & Johnson (JNJ 0.76%) reported fourth-quarter 2024 results on Wednesday, Jan. 22, that topped analyst consensus estimates. Revenue of $22.5 billion came in just ahead of forecasts for $22.4 billion while adjusted earnings per share (EPS) of $2.04 also surpassed the $1.99 estimate.
Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago.
J&J CFO Joe Wolk: Anticipating 3% operational growth in 2025 despite 'significant' headwinds
Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, slowdown in China, health care landscape in 2025, impact of the second Trump administration, and more.
J&J's stock surrenders early gains as weak sales guidance offsets earnings beat
Medtech and drug company's 2025 sales guidance is below consensus
J&J beats quarterly sales and profit estimates on cancer drug sales
Johnson & Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter sales and profit above Wall Street estimates on Wednesday, driven by strong sales of its cancer treatments.
